Cargando…

Serum metabolite profiles as potential biochemical markers in young adults with community-acquired pneumonia cured by moxifloxacin therapy

Despite the utilization of various biochemical markers and probability calculation algorithms based on clinical studies of community-acquired pneumonia (CAP), more specific and practical biochemical markers remain to be found for improved diagnosis and prognosis. In this study, we aimed to detect th...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhou, Bo, Lou, Bowen, Liu, Junhui, She, Jianqing
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7064523/ https://www.ncbi.nlm.nih.gov/pubmed/32157124 http://dx.doi.org/10.1038/s41598-020-61290-x

Ejemplares similares

Lefamulin vs moxifloxacin for community-acquired bacterial pneumonia
por: Tang, Hung-Jen, et al.
Publicado: (2020)

A brief review of moxifloxacin in the treatment of elderly patients with community-acquired pneumonia (CAP)
por: Ferrara, Anna M
Publicado: (2007)

Efficacy and safety of sequential IV/PO moxifloxacin for the treatment of severe community-acquired pneumonia
por: Lode, H, et al.
Publicado: (2002)

Altered exosomal microRNA profiles in bronchoalveolar lavage fluid can mediate metabolism in patients with Acinetobacter baumannii ventilator-associated pneumonia
por: Zhou, Bo, et al.
Publicado: (2020)

Efficacy and safety of moxifloxacin in community acquired pneumonia: a prospective, multicenter, observational study (CAPRIVI)
por: Kuzman, Ilija, et al.
Publicado: (2014)

Moxifloxacin monotherapy versus combination therapy in patients with severe community-acquired pneumonia evoked ARDS
por: Rahmel, Tim, et al.
Publicado: (2017)

Economic Evaluation of Nemonoxacin, Moxifloxacin and Levofloxacin in the Treatment of Early Community-Acquired Pneumonia with Possible Pulmonary Tuberculosis
por: Zhao, Mingye, et al.
Publicado: (2022)

Evaluation of Moxifloxacin-induced Biochemical Changes in Mice
por: Ukpo, Grace E., et al.
Publicado: (2012)

Data in Brief of: Clinical benefits of moxifloxacin as initial treatment of community-acquired pneumonia: Data from meta-analyses
por: Du, Xiwen, et al.
Publicado: (2021)

A Phase 3 Study to Compare Delafloxacin With Moxifloxacin for the Treatment of Adults With Community-Acquired Bacterial Pneumonia (DEFINE-CABP)
por: Horcajada, Juan P, et al.
Publicado: (2019)

Efficacy of Omadacycline Versus Moxifloxacin in the Treatment of Community-Acquired Bacterial Pneumonia by Disease Severity: Results From the OPTIC Study
por: Ramirez, Julio, et al.
Publicado: (2021)

Moxifloxacin modulates inflammation during murine pneumonia
por: Beisswenger, Christoph, et al.
Publicado: (2014)

The Etiology of Community-Acquired Pneumonia Correlates with Serum Inflammatory Markers in Children
por: Wrotek, August, et al.
Publicado: (2022)

Decision Analysis: Omadacycline Relative to Moxifloxacin Among Hospitalized Community-Acquired Bacterial Pneumonia Patients at Risk of Clostridioides difficile Infection
por: Lodise, Thomas P., et al.
Publicado: (2021)

Serum lipids profiling perturbances in patients with ischemic heart disease and ischemic cardiomyopathy
por: Yang, Lin, et al.
Publicado: (2020)

Epileptic Seizure after Use of Moxifloxacin in Man with Legionella longbeachae Pneumonia
por: Wang, Jin-Yong, et al.
Publicado: (2020)

Clinical characteristics and serum inflammatory markers of community‐acquired mycoplasma pneumonia in children
por: Fan, Fei, et al.
Publicado: (2023)

2232. A Global Phase 3 Study of Delafloxacin (DLX) Compared with Moxifloxacin (MOX) in Patients with Community-acquired Bacterial Pneumonia (CABP)
por: Salata, Robert, et al.
Publicado: (2019)

Diagnostic markers for community-acquired pneumonia
por: Ito, Akihiro, et al.
Publicado: (2020)

Prognostic significance of frailty in hospitalized elderly patients with community-acquired pneumonia: a retrospective cohort study
por: Zhao, Hongye, et al.
Publicado: (2023)

Serum levels of immunoglobulins and severity of community-acquired pneumonia
por: de la Torre, Mari C, et al.
Publicado: (2016)

Moxifloxacin-warfarin interaction
por: Ji, Yan, et al.
Publicado: (2012)

Dysregulated serum lipid profile and its correlation to disease activity in young female adults diagnosed with systemic lupus erythematosus: a cross-sectional study
por: Zhou, Bo, et al.
Publicado: (2020)

684. Cardiac Safety in Adults with Community-Acquired Bacterial Pneumonia (CABP) Treated with Lefamulin (LEF) or Moxifloxacin (MOX): Analysis of Lefamulin Evaluation Against Pneumonia (LEAP) 1 and LEAP 2 Study Results
por: Darpo, Borje, et al.
Publicado: (2019)

Dysregulated Arginine Metabolism in Young Patients with Chronic Persistent Asthma and in Human Bronchial Epithelial Cells
por: Zhou, Bo, et al.
Publicado: (2021)

Lipid metabolites as potential diagnostic and prognostic biomarkers for acute community acquired pneumonia
por: To, Kelvin K.W., et al.
Publicado: (2016)

Characterization of the Microbiome and Host’s Metabolites of the Lower Respiratory Tract During Acute Community-Acquired Pneumonia Identifies Potential Novel Markers
por: Xiao, Qiang, et al.
Publicado: (2023)

Efficacy of Delafloxacin versus Moxifloxacin against Bacterial Respiratory Pathogens in Adults with Community-Acquired Bacterial Pneumonia (CABP): Microbiology Results from the Delafloxacin Phase 3 CABP Trial
por: McCurdy, Sandra, et al.
Publicado: (2020)

Comprehensive clinical evaluation of moxifloxacin: A retrospective study
por: Wang, Hailiang, et al.
Publicado: (2023)

699. Hepatobiliary Safety in Adults With Community-Acquired Bacterial Pneumonia (CABP) Treated With Lefamulin (LEF) or Moxifloxacin (MOX): Pooled Analysis of Lefamulin Evaluation Against Pneumonia (LEAP) 1 and LEAP 2 Study Results
por: Lewis, James H, et al.
Publicado: (2019)

Update on the Cardiac Safety of Moxifloxacin
por: Haverkamp, Wilhelm, et al.
Publicado: (2012)

The role of moxifloxacin in tuberculosis therapy
por: Gillespie, Stephen H.
Publicado: (2016)

Steroids in severe community-acquired pneumonia: dangerous, worthless, or miracle cure? The roller coaster of clinical trials
por: Bouras, Marwan, et al.
Publicado: (2023)

Moxifloxacin Concentration and Proteomic Analysis of Aqueous Humor in Human Uveitis Associated with Oral Moxifloxacin Therapy
por: Hinkle, David M, et al.
Publicado: (2017)

Impact of Age, Sex, and Renal Function on the Efficacy and Safety of Direct Oral Anticoagulants vs. Vitamin K Antagonists for the Treatment of Acute Venous Thromboembolism: A Meta-Analysis of 22,040 Patients
por: Zhou, Bo, et al.
Publicado: (2021)

2386. Efficacy of Lefamulin (LEF) vs. Moxifloxacin (MOX) Against Common Pathogens in Adults With Community-Acquired Bacterial Pneumonia (CABP): Results From the Phase 3 Lefamulin Evaluation Against Pneumonia (LEAP 1) Study
por: File, Thomas, et al.
Publicado: (2018)

Serum biochemical markers in lung cancer.
por: Burt, R. W., et al.
Publicado: (1978)

Procalcitonin as a Marker of Etiology in Adults Hospitalized With Community-Acquired Pneumonia
por: Self, Wesley H., et al.
Publicado: (2017)

Predictive value of copeptin as a severity marker of community-acquired pneumonia
por: Mohamed, Gamal Baheeg, et al.
Publicado: (2017)

Clinical characteristics and protective factors in patients with acute myocardial infarction undergoing in-hospital myocardial free wall rupture: a single-center, retrospective analysis
por: Lou, Bowen, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_7ivkh4vhl1tnfd1jio67t8sq15